Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124)(NSE:DRREDDY) (NYSE:RDY) on Wednesday announced the availability in the US of Sapropterin Dihydrochloride Powder for Oral Solution in 100 mg.
The company added that Sapropterin Dihydrochloride Powder for Oral Solution in 100 mg is a therapeutic equivalent generic version of Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the US Food and Drug Administration (USFDA).
According to the company, Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.
KUVAN (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution are prescription medicines used to lower blood Phe levels in adults and children over one month of age with a certain type of Phenylketonuria (PKU), a genetic condition that causes increased levels of phenylalanine (an amino acid) in the body, concluded the company.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval